PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Orforglipron taken orally once daily leads to significant body weight loss (ATTAIN-1 Study)

Results of this landmark trial are especially important as oral therapies for obesity may offer greater access and affordability to obesity medications; in addition, many patients prefer oral to injectable medications

2025-09-16
(Press-News.org) New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes. The study is by Dr Sean Wharton, McMaster University, Hamilton, ON, Canada and Wharton Weight Management Clinic, Burlington, ON, Canada, and colleagues. The study is sponsored by Eli Lilly, the manufacturer of orforglipron. 

Orforglipron is a small-molecule, oral glucagon-like peptide-1 (GLP-1) receptor agonist. In this phase 3, multinational, randomised, double-blind trial, the authors examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity but not diabetes. The primary end point was the percent change in body weight from baseline to week 72.

A total of 3127 patients in 9 countries / jurisdictions (USA, China, Brazil, India, Japan, South Korea, Spain, Slovakia and Taiwan) underwent randomisation. The mean relative change in body weight from baseline to week 72 was −7.5% with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron, and −11.2% with 36 mg of orforglipron, as compared with −2.1% with placebo.

Among the patients in the orforglipron 36 mg group, 54.6% had reduction of 10% or more of body weight, 36.0% had a reduction of 15% or more, and 18.4% had a reduction of 20% or more, as compared with 12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group.

Other outcomes such as waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment (see table 3 full paper). Adverse events (see table 4) resulted in treatment discontinuation in 5.3% to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group. The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate, consistent with the GLP-1 class of medications.

The authors note that the use of medications such as GLP-1 receptor agonists (such as semaglutide) are reported to result in mean weight reductions of approximately 15% to above 20% and have shown additional health benefits, including decreased cardiovascular risk. However, most available GLP-1 based medications are administered as a subcutaneous injection, which may limit treatment initiation and adherence.

The authors say: “After 72 weeks of treatment, all the patients in the three orforglipron groups had a significant and clinically meaningful dose-dependent reduction in body weight. The patients who received the highest dose of orforglipron had an average 11.2% weight reduction; more than one third had a reduction of at least 15%, and nearly one fifth had a reduction of at least 20%. All measured cardiometabolic levels improved with orforglipron treatment as compared with placebo… A weight reduction of 10% or more is a recognised therapeutic threshold, one that has been linked to meaningful cardiometabolic benefits. In our current trial, patients who received orforglipron had a mean weight reduction of as much as 11.2%, and such reductions were associated with improvements in levels of systolic and diastolic blood pressure, as well as blood fats, blood sugar profiles, and high-sensitivity C-reactive protein – a marker of systemic inflammation.”

The authors note the trial’s limitations include the lack of comparison with currently approved obesity-management medications, the use of cutoffs for BMI inclusion criteria that have been developed in White populations and that exclude patients with lower BMI values who may also have adiposity-related risks, and the increasing availability of obesity-management medications, which could have an effect on treatment adherence and efficacy results. The strengths of the trial include a highly diverse, large population from nine countries and jurisdictions on four continents - including more than 35% enrolment of men.

They conclude: “In patients with obesity, the use of orforglipron resulted in statistically and clinically significant weight reductions and an adverse-event profile that was consistent with findings regarding other GLP-1 receptor agonists.”

Dr Wharton adds: “This could mean an expansion of obesity interventions to groups who are currently excluded due to the cost of and lack of access to injectable medications.”

Orforglipron is not yet approved by the US Food and Drug Administration (FDA) or other similar agencies worldwide. 

 

 

 

END


ELSE PRESS RELEASES FROM THIS DATE:

U of I researchers trace genetic code’s origins to early protein structures

2025-09-16
URBANA, Ill. – Genes are the building blocks of life, and the genetic code provides the instructions for the complex processes that make organisms function. But how and why did it come to be the way it is? A recent study from the University of Illinois Urbana-Champaign sheds new light on the origin and evolution of the genetic code, providing valuable insights for genetic engineering and bioinformatics. “We find the origin of the genetic code mysteriously linked to the dipeptide composition of a proteome, the collective of proteins in an organism,” said corresponding author Gustavo Caetano-Anollés, professor in the Department ...

Disease experts team up with Florida Museum of Natural History to create a forecast for West Nile virus

2025-09-16
Key points State and local officials in Florida maintain hundreds coops with what are referred to as sentinel chickens, which act as an early alarm system for the presence of mosquito-borne illnesses in an area. This alarm system just got an upgrade. An interdisciplinary team of experts, including a zoonotic disease specialist, a museum data scientist and a salamander biologist, have combined their skills and created a statistical model that accurately predicts the activity of West Nile virus in an area up to six months in advance. The model was trained using two decades of sentinel chicken data. The original data files ...

Researchers: Targeted efforts needed to stem fentanyl crisis

2025-09-16
A new study illuminates how some areas of the country have been hit much harder than others by the fentanyl epidemic, which took more than 70,800 lives in 2022 alone. The research calls attention to a need for focused, coordinated efforts to prevent overdose deaths in the places where deaths from the opioid are rampant, said lead author Thomas Wickizer, a professor emeritus in The Ohio State University College of Public Health. The study appears in the journal Health Affairs Scholar. “We can look at this map and see there are certain areas which are experiencing this at an extremely dire rate, and energy and resources, including financial investments, should ...

New UMaine research could help lower prescription drug costs

2025-09-16
One of the main factors driving prices in pharmaceuticals, such as cholesterol-lowering drugs and antibiotics, is the cost of production and materials. Researchers at the University of Maine Forest Bioproducts Research Institute (FBRI) have discovered a sustainable method to produce the key ingredient in a broad range of pharmaceuticals, which could help address high prescription drug costs in the U.S.  Among some of the most expensive medications are those that require a chiral center  ― a property in which a molecule cannot be superimposed with its mirror image, like right and ...

Molecular movie shows how mitochondria read their DNA

2025-09-16
Aging, neurological diseases and our bodies’ stress response are all linked to the tiny power plants inside each cell known as mitochondria. To function properly, mitochondria must first read instructions from their DNA and then copy it over into mRNA in a process called transcription. Now, researchers at Thomas Jefferson University have reconstructed transcription in human mitochondria in unprecedented detail. The findings, published in Molecular Cell, show how the molecular machinery works and reveal potential drug targets for mitochondrial diseases. “When we understand ...

Loss of key male fertility gene leads to changes in expression of hundreds of other genes

2025-09-16
In a new study conducted at the University of Hawaiʻi at Mānoa, researchers from the John A. Burns School of Medicine (JABSOM) have shown that the loss of a key male fertility gene leads to infertility and changes expression of hundreds of other important genes. The study was led by Professor Dr. Monika Ward from the Department of Anatomy, Biochemistry & Physiology and the Yanagimachi Institute for Biogenesis Research (YIBR). The team has been investigating a zinc finger Y-encoded gene called Zfy. This gene, encoded on Y chromosome in both mice and humans, is considered a male fertility factor. In mice, Zfy is present as two copies, Zfy1 and Zfy2. The researchers ...

Water’s density is key to sustainable lithium mining

2025-09-16
AMHERST, Mass. — One of the biggest obstacles on the road to the low-carbon energy future is caused by the rare-earth element lithium, a critical component for the batteries that can store the abundant and sustainable energy from renewable sources. The element occurs naturally as a salt in briny oases, called salares, in some of the world’s harshest environments, including the “Lithium Triangle” high in South America’s arid Altiplano. Mining lithium has the potential to destabilize already sensitive environments that are host to rare flora and fauna, ...

Pioneering research reveals problem gambling quadruples the risk of suicide among young people four years later

2025-09-16
New research has shown how harmful gambling is clearly linked to a marked and long-lasting increase in suicide attempts among young people in the UK. The study, by researchers at the University of Bristol, found that compared to someone who experiences no gambling harms, problem gamblers face triple the suicide risk one year later, and quadruple the risk four years on. Researchers analysed data from 2,801 people in the renowned Children of the 90s study, which has followed the health and development of 14,000 pregnant women and their families since the early nineties, and which continues ...

New method improves the accuracy of machine-learned potentials for simulating catalysts

2025-09-16
Catalysts play an indispensable role in modern manufacturing. More than 80% of all manufactured products, from pharmaceuticals to plastics, rely on catalytic processes at some stage of production. Transition metals, in particular, stand out as highly effective catalysts because their partially filled d-orbitals allow them to easily exchange electrons with other molecules. This very property, however, makes them challenging to model accurately, requiring precise descriptions of their electronic structure. Designing efficient transition-metal catalysts ...

Astronomers discover rare Einstein cross with fifth image, revealing hidden dark matter

2025-09-16
When Rutgers theoretical astrophysicist Charles Keeton first saw an unusual picture shared by his colleague, he was intrigued. “Have you ever seen an Einstein Cross with an image in the middle?” his colleague Andrew Baker asked, referring to a rarely seen cosmic configuration. Keeton hadn’t. The implications were enormous. “I said, well, that’s not supposed to happen,” said Keeton, the Vice Provost for Experiential Learning at Rutgers University-New Brunswick. “You can’t get a fifth image in the center unless something unusual is going on with the mass that’s bending the light.” An ...

LAST 30 PRESS RELEASES:

Bipolar disorder heterogeneity decoded: transforming global psychiatric treatment approaches

Catching Alport syndrome through universal age-3 urine screening

Instructions help you remember something better than emotions or a good night’s sleep

Solar energy is now the world’s cheapest source of power, a Surrey study finds

Scientists reverse Alzheimer’s in mice using nanoparticles

‘Good’ gut bacteria boosts placenta for healthier pregnancy

USC team demonstrates first optical device based on “optical thermodynamics”

Microplastics found to change gut microbiome in first human-sample study

Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds

Plastic in the soil, but not as we know it: Biodegradable microplastics rewire carbon storage in farm fields

Yeast proteins reveal the secrets of drought resistance

Psychiatry, primary care, and OB/GYN subspecialties hit hardest by physician attrition

New Canadian study reveals where HIV hides in different parts of the body

Lidocaine poisonings rise despite overall drop in local anesthetic toxicity

Politics follow you on the road

Scientists blaze new path to fighting viral diseases

The mouse eye as a window to spotting systemic disease

AI and the Future of Cancer Research and Cancer Care to headline October 24 gathering of global oncology leaders at the National Press Club: NFCR Global Summit to feature top scientists, entrepreneurs

FDA clears UCLA heart tissue regeneration drug AD-NP1 for clinical trials

Exploring the therapeutic potential of cannabidiol for Alzheimer's

We need a solar sail probe to detect space tornadoes earlier, more accurately, U-M researchers say

Acute myeloid leukemia (AML): Disease risk but not remission status determines transplant outcomes – new ASAP long-term results

Sperm microRNAs: Key regulators of the paternal transmission of exercise capacity

Seeing double: Clever images open doors for brain research

Inhaler-related greenhouse gas emissions in the US

UCLA Health study finds inhalers for asthma and COPD drive significant greenhouse gas emissions

A surgical handover system for patient physiology and safety

Cardiovascular health changes in young adults and risk of later-life cardiovascular disease

Nurse workload and missed nursing care in neonatal intensive care units

How to solve the remote work stalemate – dissertation offers tools for successful hybrid work

[Press-News.org] Orforglipron taken orally once daily leads to significant body weight loss (ATTAIN-1 Study)
Results of this landmark trial are especially important as oral therapies for obesity may offer greater access and affordability to obesity medications; in addition, many patients prefer oral to injectable medications